• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CSL
Click for more information
0.55% $288.61

CSL LIMITED - Corporate Spotlight

Market Cap $139.7B  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus... CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with more than 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China. Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam and others. More

No Corporate Spotlight currently available.

(20min delay)
Last
$288.61 		Change
1.590(0.55%) 		Mkt cap ! $139.7B
Open High Low Value Volume
$289.01 $289.50 $287.03 $102.6M 356.0K

Buyers (Bids)

No. Vol. Price($)
1 2 $288.59
 

Sellers (Offers)

Price($) Vol. No.
$288.79 200 1
View Market Depth
Last trade - 16.10pm 03/10/2024 (20 minute delay) ?
Last
$288.66 		  Change
1.590 ( 0.54 %)
Open High Low Volume
$289.08 $289.49 $287.05 114111
Last updated 15.59pm 03/10/2024 ?
CSL (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Firefly positioned for copper growth in Canada ahead of resource update Firefly Metals Ltd has reported drilling reports from its Green Bay copper-gold project in Newfoundland, ahead of a resource update
Chariot Corp unveils plans for Black Mountain "pilot mine" in Wyoming, US; shares jump +20% Chariot has unveiled its vision for its US-based Black Mountain – aiming to fast-track its path to production by establishing a "pilot mine."
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.